Janux Therapeutics(JANX) - 2025 Q4 - Annual Results

Exhibit 99.1 Janux Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights SAN DIEGO, February 26, 2026 – Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided a business update. "The past year marked a period of significant execution and progress for Janux as we continu ...